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Aging is a universal, intrinsic, and time-dependent biological decay that is linked to 
intricate cellular processes including cellular senescence, telomere shortening, stem cell 
exhaustion, mitochondrial dysfunction, and deregulated metabolism. Cellular senescence 
is accepted as one of the core processes of aging at the organism level. Understanding 
the molecular mechanism underlying senescence could facilitate the development of 
potential therapeutics for aging and age-related diseases. Recently, the discovery of 
long non-coding RNAs (lncRNA) provided insights into a novel regulatory layer that can 
intervene with cellular senescence. Increasing evidence indicates that targeting lncRNAs 
may impact on senescence pathways. In this review, we will focus on lncRNAs involved 
in mechanistic pathways governing cellular senescence.
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iNTRODUCTiON
Aging is a time-dependent decline of physiological capabilities. This progressive decay is caused by 
multiple factors such as the accumulation of senescent cells, mitochondrial dysfunction, disruption 
of inter/intracellular signaling, and impairment of metabolic homeostasis. Physiological degenera-
tion is the primary risk factor for the age-related diseases such as Alzheimer, cancer, and type-2 
diabetes. World population over 60 is expected to double and reach 22% by 2050 while countries like 
Japan, UK, Germany, and Finland will reach that level in next 5 years, and these statistics are calling 
for further study of aging biology (1).
Cellular senescence can be activated by mitochondrial dysfunction, chromosome destabiliza-
tion, telomere attrition, DNA damage, and many other stress factors especially those linked to cell 
cycle. Clearance of senescent cells (p16INK4A positive cells) was shown to elongate lifespan in mouse 
models (2), which supports the idea of the cellular senescence as being one of the contributing 
factors to the organism aging. Other factors such as immune system clearance defect, shorter 
telomere size, and accumulation of mutations are also pushing forward the physiological decline 
during aging. However, a consensus view regarding their relative contributions to aging has yet 
to merge.
Pathologic effects of senescent cells may impact on overall body due to accumulation of them 
during aging. The emerging evidence suggests that cellular senescence can affect organisms in at least 
three different stages. First, senescence impairs tissue regeneration due to exhaustion of stem cells. 
Second, senescent cells release cytokines and chemokines to interact with other cells, which can result 
in malfunction at tissue or organism level, a phenotype known as senescence-associated secretory 
Abbreviations: CDKN1, cyclin-dependent kinase inhibitor 1; CHK, checkpoint kinase; DDR, DNA damage response; GWAS, 
genome-wide association study; hnRNP, heterogeneous nuclear ribonucleoproteins; lncRNA, long non-coding RNA; MEF, 
mouse embryonic fibroblast; ORF, open reading frame; PRC, polycomb repressor complex; SAHF, senescence-associated het-
erochromatin foci; SASP, senescence-associated secretory phenotype; SCNA, somatic copy number alterations; SMD, staufen1 
(STAU1)-mediated mRNA decay; UTR, untranslated region.
FiGURe 1 | Cellular senescence occurs in three stages: activation of the signaling cascade, the response of the cell by activation of p53–p21/p16 
pathways, and late stage when SAHFs are formed and SASP factors are released to cause organ level malfunctions and pathologies.
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phenotype (SASP) (3–9). SASP can explain how relatively low 
number of cells can cause problems in organs and overall body 
performance. Third, cellular senescence could intervene with 
mitochondrial and cellular metabolism through stress activa-
tion that results in disturbed energy homeostasis. In contrasts, 
cellular senescence seems to have a protective function against 
tumor formation by limiting cellular replication that is consistent 
with the interception of senescence pathway with tumor response 
pathways.
Hayflick and Moorehead challenged the cellular immortality 
idea with their findings on the limit of cellular replication after 
extensive passaging (10, 11). Later, this senescence type has been 
linked to telomere attrition, a process that causes chromosomal 
instability and activates DNA damage response (DDR), which is 
now known as replicative senescence (4). The DDR pathway is 
a signal transduction pathway comprised of multiple interact-
ing components. It is initiated by ATM and ATM-Rad3-related 
(ATR). Downstream of these proteins are checkpoint kinases 
(CHK1 and CHK2) that phosphorylate and activate downstream 
effectors such as p53 and p21. Besides telomere attrition, other 
factors such as UV, oncogenic insult, and chemotherapeutics 
can also activate DDR and initiate cellular senescence (11–18). 
In addition, loss of PTEN (tumor suppressor) and overexpression 
of E2F3 (the S-phase transcription factor) can initiate p53–p21 
pathway (19–21).
Senescence activation also occurs through p16INK4A, which 
represses the CDK4–6-mediated phosphorylation of pRB, 
thereby blocking cell cycle. This pathway may coordinate with 
the p53–p21 response, depending on stress signal and/or cell 
types (3, 22–30).
In vitro senescent cells have distinctive characteristics such 
as increased cell size, accumulation of senescence-associated 
β-galactosidase (SA-β-GAL), activation of survival genes to 
avoid apoptosis, and the production of the SASP (7, 31–34). 
The discovery of the SASP provided clues to how senescent cells 
could disrupt the overall homeostasis of the body albeit their 
relatively low number. The presence of SASP in mammalian cells 
appeared to be conserved, and some of the proteins in secretome 
have been repeatedly detected in multiple cell type. Another 
senescence-linked phenotype is the formation of senescence-
associated heterochromatin foci (SAHFs), which is mainly medi-
ated by p16–pRB pathway. These foci often exist in the genomic 
loci harboring proliferative genes, thereby inhibiting their 
expression and activity, but it is important to keep in mind that 
SHAF does not exist in all senescent cells (35). In senescent cells 
lacking SAHFs, p16–pRB pathway silences proliferative genes on 
the epigenetic level as compensatory pathway (36). Currently, 
measurement of multiple traits mentioned above is the best 
way to identify senescent cells since each cell type can develop 
the phenotype with varying order and composition (Figure 1). 
Figure 1 shows the generic process for cellular senescence while 
it does not imply the existence of each component in all senes-
cent cells (37–39). Table 1 also indicates specific lncRNAs and 
their targets.
TABLe 1 | lncRNAs are here listed with their targets, cell type, and 
organism in which the experiments performed.
LncRNA name Target Cell type Organism/
system
FAL1 p21 Cancer cells Human/in vitro
BANCR p21 Colorectal cancer cells Human/in vitro
LINCRNA-p21 p21 Mouse embryonic 
fibroblasts
Mouse/in vivo 
and in vitro
MALAT1 p53 Human osteosarcoma 
cells
Human/in vitro
7SL p53 HeLa cells Human/in vitro
VAD INK4 locus/
p16INK4a
hTERT-immortalized 
WI38 human fibroblasts
Human/in vitro
ANRIL INK4 locus/
p16INK4a
WI38 cell line Human/in vitro
MIR31HG INK4 locus/
p16INK4a
Immortalized human 
diploid fibroblasts, 
TIG3-hTERT
Human/in vitro
UCA1 p16INK4a 
mRNA
Mouse primary cells Mouse/in vitro
SAL-RNA p53 WI38 cell line (old 
versus young)
Human/in vitro
SALNR NF-90 
localization
Human fibroblast cells Human/in vitro
TERRA Telomere length Mammalian cells and 
medulloblastoma
ASNCMTRNA2 hsa-miR-4485 Human endothelial cells Human/in vitro
HOTAIR E3 ubiquitin 
ligase and 
PRC2
Ovarian cancer cells 
and HeLa cells
Human/in vitro
PANDA PRC1 and 
PRC2 
recruitment
Primary human diploid 
fibroblast strains, BJ 
(neonatal foreskin), and 
WI38 (fetal lung)
Human/in vitro
Same list was also used during generation of Figure 2.
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eMeRGiNG ReGULATORY LAYeR OF 
DiveRSe BiOLOGiCAL PROCeSSeS
With protein-coding genes making up to only 2% of the human 
genome, the other 98% have been considered “junk DNA” till 
the encyclopedia of DNA elements (ENCODE) project and the 
functional annotation of the mammalian genome (FANTOM) 
consortium made their early release. They have challenged this 
concept by identifying a large number of novel transcripts, 
namely non-coding RNAs (ncRNAs), from the “junk” regions. 
Based on their transcript lengths, ncRNAs were further divided 
into small ncRNAs and long ncRNAs (lncRNAs). lncRNAs are 
a major class of heterogeneous ncRNAs with the lengths more 
than 200 nucleotides. They are now being recognized as novel 
regulators in multiple cellular processes, including development, 
differentiation, chromosome remodeling, imprinting, and cell 
cycle control (40–44). Research also shows that lncRNAs are 
tightly regulated and highly tissue specific (43). Moreover, dys-
regulation of lncRNAs has been associated with human diseases, 
such as cancer or neurodegenerative disorders (45). However, the 
functions of most lncRNAs remain uncharacterized (46, 47).
Long non-coding RNAs often contain a small open reading 
frame similar to mRNAs, which was a challenge on their distinc-
tion (48). Ribosome-profiling experiments have been employed 
to address this issue. Initial results of ribosome profiling showed 
that many lncRNAs were, in fact, ribosome-bound while high 
sensitivity mass spectrometry failed to identify those small 
peptides from supposed “lncRNA ORFs” (49). With the help of 
bioinformatics, ribosome release score has been calculated for 
protein-coding and non-coding RNAs. Ribosome release score is 
produced by using ribosome dissociation and association values 
of given part of RNA. Using this score, most lncRNAs fall into 
the non-coding category, supporting the results of previous mass 
spectrometry experiments (44, 50).
Regulatory role of lncRNAs in gene expression has been stud-
ied. According to these research, their molecular mechanism is 
quite versatile and there are multiple modes of action (40, 51). 
lncRNAs may regulate gene expression at transcriptional, RNA 
processing, translational or posttranslational levels by interacting 
with DNA, RNA, or protein molecules. The subcellular localiza-
tion of lncRNAs may also provide additional complexity to their 
function (52).
Most of the lncRNAs are enriched in the nucleus (43, 53), and 
their localization supports their suggested role in the epigenetic 
regulation of the chromatin (54, 55). They function in cis to 
regulate the expression of nearby genes or in trans to regulate 
genes from distant genomic locations. Nuclear lncRNAs often 
bind to heterogeneous ribonucleoprotein complexes (hnRNPs) 
and polycomb repressor complex (PRC), consistent with their 
involvement in modulating epigenetic markers and interacting 
with transcription factors of target genes. One of the well-known 
nuclear lncRNAs, Xist, is transcribed from the inactive X chromo-
some, and it controls dosage compensation of chromosome X in 
human females (56). Xist recruits polycomb repressive complex 2 
(PRC2) (56) that switches histone markers to repressive state, and 
it inhibits transcription of target genes by blocking the access of 
RNA polymerase II (RNAPII) to inactivated X chromosome (57, 
58). PRCs are one of the major binding partners of lncRNAs that 
has been identified so far. This affinity is explained by intrinsic 
promiscuity of PRCs and lncRNAs ability to guide PRCs.
Although lncRNAs are generally enriched in the nucleus, 
many lncRNAs are also detectable in the cytosol. lncRNAs can 
control mRNA stability by acting as “sponge” for miRNAs in the 
cytosol. Sponge lncRNAs compete for the miRNA binding site, 
which results in rescued expression of mRNAs (59). lncRNAs 
can also associate with a coding gene by overlapping exons to 
increase the stability of the target mRNA, e.g., BACE1-AS. In 
contrast, lncRNAs may also be involved in mRNA degradation 
through Staufen1 (STAU1)-mediated mRNA decay (SMD). This 
process recognizes double-stranded RNA for degradation. It 
has been shown that lncRNAs can form RNA-RNA duplex with 
3′-UTRs of target mRNA at Alu elements and cause SMD (60). 
lncRNA–mRNA complex (bound by Alu element) can be the 
result of imperfect base pairing, and this double-stranded RNA 
4Degirmenci and Lei Role of lncRNAs in Cellular Aging
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 151
complex activates SMD, which happens through recruitment 
of UPF1 (regulator of nonsense transcript-1) that shortens the 
poly-A tail. Shortened poly-A translates to the shorter lifespan 
for mRNA (61). Another function is that H19 is transported to 
the cytosol, where it is used as a source of microRNA (miR-675) 
to suppress growth (62–71).
In this review, we will focus on the recent studies about 
lncRNAs involved in cellular senescence (66, 72–77). To incor-
porate lncRNAs into the known regulatory network, we discussed 
lncRNAs according to their interactions with known key proteins 
such as p53/p21, p16, CDKs, and pRb (3–5, 12, 15, 23–25, 27, 28, 
30, 78, 79) (Figure 2).
lncRNAs ARe iNvOLveD iN p21 
PATHwAY ReGULATiON (CDKN1A-p21)
Several lncRNAs, as discussed below, have been reported to 
modulate expression of p21 in different ways. Although the 
involvement of these p21-regulating lncRNAs in aging has 
not been directly demonstrated, given the key role of p21 in 
cellular senescence, it warrants further investigation on how 
these lncRNAs may participate in cellular senescence regulation 
through p21.
Focally Amplified lncRNA  
on Chromosome 1
Hu et al. focused on somatic copy number alterations (SCNAs) 
of lncRNAs. By analyzing a genome-wide survey on SCNAs 
of lncRNA in 2394 tumor specimens from 12 types of cancer, 
they identified a correlation between copy number of focally 
amplified lncRNA on chromosome 1 (FAL1) and progression of 
ovarian cancer. They found out that FAL1 interacts and stabilizes 
the epigenetic repressor BMI1 (the PRC1 core protein) so as to 
repress p21 expression. Silencing FAL1 with siRNAs significantly 
blocked tumor growth in  vivo. The interaction between FAL1 
and BMI1 highlights how lncRNAs can take a central role in 
epigenetic regulation of p21 (80, 81).
BRAF-Activated Non-Coding RNA
BRAF-activated non-coding RNA (BANCR) is a lncRNA 
required for cell migration in different types of cancer (82–84). 
Shi et al. investigated its contribution to colorectal cancer. They 
showed that BANCR expression was significantly decreased in 
colorectal cancer, and when BANCR is overexpressed, it slowed 
down the growth of colorectal cancer. They also suggested that 
pcDNA-BANCR-mediated proliferation was linked to activa-
tion of G0/G1 cell cycle arrest through regulation of p21. Effects 
of BANCR were probably post-transcriptional since protein 
expression levels of p21 increased while that of mRNA remained 
unchanged. In brief, this article suggests that downregulation 
of BANCR contributes to the translational regulation of p21 
protein (85).
LincRNA-P21
LincRNA-p21 plays a role in regulating p21 levels. Upon DNA 
damage, p53 activates lincRNA-p21 that is located next to the 
p21 gene. In the nucleus, lincRNA-p21 activates transcription 
of p21 by recruiting hnRNP-K to the promoter region of p21 
(86). Using conditional lincRNA-p21 knockout mouse model, 
Dimitrova et  al. showed that loss of lincRNA-p21 could block 
p21 expression and it can activate mouse embryonic fibroblasts 
(MEFs) expansion. In the cytoplasm, lincRNA-p21 bound HuR 
recruits the let-7/Ago2 complex to destabilize lincRNA-p21. 
LincRNA-p21 also associates with its target mRNAs by base pair-
ing and suppresses their translation with the Rck RNA helicase 
(86, 87).
lncRNAs iNvOLveD iN p53 ReGULATiON
Metastasis-Associated Lung 
Adenocarcinoma Transcript 1
The transcript of metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1) gene was first identified in 1997 (88), 
and it is highly expressed in several type of cancers (89). In 
2010, MALAT1 was reported as a highly abundant nuclear 
transcript localized to the nuclear speckles (a region which 
is enriched in pre-mRNA splicing factors) (90, 91). In 2013, 
Tripathi et  al. performed genome-wide transcriptome analyses 
in human fibroblasts. Their result indicated that MALAT1 
controlled the expression of cell cycle genes and was required 
for cell cycle progression (92). They also showed that depletion 
of MALAT1 leads to activation of the p53 pathway and p53 is 
required for MALAT1 dependent cell cycle arrest. Moreover, 
MALAT1-depleted cells have low levels of B-MYB (Mybl2, an 
oncogenic transcription factor), leading to the discovery of 
aberrant alternative splicing of B-MYB pre-mRNA. However, 
the exact mechanism of how MALAT1 impacts p53 signaling 
needs further investigation (91, 92).
7SL
In 1991, Sakamoto et al. cloned 7SL sequence partially (93). They 
observed the 7SL would block proliferation of HeLa cells. Recently, 
Abdelmohsen et al. showed that 7SL forms a partial hybrid with 
the 3′-untranslated region (UTR) of p53 mRNA. The association 
of 7SL with p53 mRNA reduced p53 translation. When 7SL were 
silenced, it increased the interaction between HuR and TP53 
mRNA, stabilizing TP53 mRNA and increasing p53 translation. 
The antagonist activity between 7SL and HuR for TP53 3′ UTR 
contributes to the fine tuning of p53 translation (94).
lncRNAs ReGULATiNG CDKN2A
Very long intergenic non-coding RNA-vlincRNA antisense to 
DDAH1 (VAD) and ANRIL have been identified from senescent 
cells and found to have an impact on cellular senescence while 
MIR31HG and UCA1 have been identified through oncogenic 
pathways.
very Long intergenic Non-Coding  
RNA-vlincRNA Antisense to DDAH1
Lazorthes et al. have analyzed the differentially expressed strand-
specific transcription during oncogene-induced senescence 
FiGURe 2 | Senescence activation pathways is shown side by sides from both in human and mouse. Long lines with small gaps suggest additional 
unknown intermediates. lncRNAs reviewed in this article have been located as to match their organism. P16INK4A is the major component of senescence in human 
cells while p19ARF is the main activator in mouse (shown with thicker lines).
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in human. They identified that most vlincRNAs (>50  kb) are 
induced during senescence. They showed that VAD, one of the 
antisense vlincRNAs, was highly expressed during senescence 
and it is essential for maintaining senescence phenotype. VAD 
regulates chromatin structure in cis and activates gene expression 
in trans at the INK4 locus. Moreover, VAD blocks the recruitment 
of H2A.Z, repressive histone variant, into the proximity of INK4 
gene in senescent cells and maintains transcription of it (95).
6Degirmenci and Lei Role of lncRNAs in Cellular Aging
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Antisense Non-Coding RNA in the 
iNK4 Locus, CDKN2B-AS
Antisense non-coding RNA in the INK4 locus is produced 
from 9p21 on human chromosome locus where p16 INK4A and 
p15INK4B (p15 in mouse) are transcribed. SNPs in ANRIL gene 
are linked to various diseases in genome-wide association stud-
ies (GWAS). Additionally, silencing of this locus affects cellular 
proliferation, and it has been found that polycomb complex is 
recruited to this region by ANRIL via SUZ12 (a component of 
polycomb complex). Silencing of ANRIL produces senescent 
cells that are stained positive for beta-galactosidase. Current 
research suggests that ANRIL recruits PRC1 and PRC2 to 
INK4 region to initiate and maintain silenced chromatin 
signature: H3K27ME and H2AK119ub1 (96, 97). Therefore, 
ANRIL maintains the proliferative state by blocking senescence 
genes.
MiR31 Host Gene
MIR31 host gene is located 400 kb upstream of the p16INK4A locus 
on chromosome 9 in human. Previously, decreased expression 
of MIR31HG has been shown to reduce cell growth and activate 
strong senescence phenotype (98). Recently, Montes et al. found 
that the lncRNA MIR31HG was highly expressed in senescence 
and silencing of MIR31HG activates p16INK4A expression (99). 
In pre-senescent cells, MIR31HG is located in both nucleus 
and cytoplasm, but after B-RAF (proto-oncogene) transcrip-
tion, MIR31HG is specifically present in the cytoplasm. Their 
results showed that MIR31HG could bind to both p16INK4A and 
MIR31HG genomic regions. Additionally, polycomb group 
(PcG) proteins and MIR31HG are necessary for PcG-mediated 
repression of the p16INK4A locus. Hence, their data suggested a new 
lncRNA-mediated inhibition of the p16INK4A (99).
Urothelial Cancer-Associated 1
Kumar et al. discovered that CAPERα/TBX3 repressor complex 
was required to prevent senescence in primary cells and mouse 
embryos. CAPERα/TBX3 complex regulates chromatin struc-
ture and represses transcription of CDKN2A-p16. Inhibiting 
CAPERα/TBX3 induced the lncRNA UCA1 expression, in 
which UCA1 overexpression induced senescence. In proliferat-
ing cells, hnRNPA1 can bind and destabilize p16INK4A mRNA. 
However, during senescence, UCA1 expression stabilizes 
p16INK4A mRNAs by disrupting the association of hnRNP A1 
with p16INK4A mRNA (100, 101).
ACTivATiON OF SeNeSCeNCe THROUGH 
OTHeR PATHwAYS
Senescence-Associated lncRNAs
Abdelmohsen et  al. identified differentially expressed novel 
lncRNAs between young versus old human diploid WI-38 
fibroblasts populations. These populations are 32  days apart 
from each other in doubling time. Among those novel lncRNAs, 
they selected three lncRNAs to further study their involvement 
in cellular senescence and proliferation. Decreasing expression 
of those lncRNAs resulted in increased p53 expression, thereby 
affecting cell survival and senescence (102). However, exact 
mechanism requires further study.
Senescence-Associated Long  
Non-Coding RNA
Using human fibroblast cells, Wu et al. performed genome-wide 
screening of lncRNA expression in cellular senescence. They have 
identified lncRNAs with differential expressions in senescent cells 
in contrast with young cells. Within these lncRNAs, they further 
selected a specific senescence-associated lncRNA (SALNR) that 
has low expression in senescent cells. When they overexpressed 
the SALNR, cellular senescence was delayed.
Furthermore, they found that SALNR physically interacts 
with NF90 (nuclear factor of activated T-cells, 90 kDa), which 
is able to suppress biogenesis of senescence-associated miRNAs, 
such as miR-22 and miR-181a. Inhibiting NF90 resulted in pre-
mature senescence since NF90 is the suppressor of senescence 
miRNAs.
Moreover, when cells were exposed to Ras-induced stress 
(activates senescence), NF90 gets translocated to nucleolus 
and NF90 can no longer suppress senescence-associated 
miRNA biogenesis, which can be rescued by SALNR overex-
pression. Thus, SALNR antagonizes NF90 translocation into 
nucleolus and rescues its inhibitory activity on senescence- 
associated miRNA expression. Their data suggest that lncRNA 
SALNR controls cellular senescence through modulating NF90 
 localization (103).
Telomeric Repeat-Containing RNA
First, telomeric repeat-containing RNA has been identified in 
yeast and it has a specific hotspot in the subject of senescence. 
It forms DNA–RNA pairing with telomere region at R-loop 
formation that contains G-quadruplex, TERRA, and TERRA-
binding proteins. TERRA also increases upon DNA damage 
at telomere region to involve in recombination and DNA 
repair. Arnoult et al. showed that TERRA expression decreases 
upon telomere elongation in multiple cancer cell lines (104). 
Elongated telomeres have less TERRA expression due to 
tightly packed telomeric repeats with HP1α and H3K9me3, 
which make chromosome inaccessible to the transcription 
machinery.
In parallel, increased levels of TERRA was also found in sev-
eral primary human tumors containing short telomeres (105). 
In other words, TERRA is reversely correlated with telomere 
length.
On a different research, TERRA was shown to maintain the 
telomere length in the lack of telomerase enzyme as explained 
above. RNA–DNA complex formed between TERRA and 
telomeres postpones the senescence by activating homologous 
recombination at telomeres (106). These suggest multiple func-
tions for TERRA on telomere length and maintenance; however, 
further research is required to unravel the detailed mechanism 
of how TERRA functions in telomere and telomerase during 
aging (107–109).
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MiTOCHONDRiAL lncRNA iNvOLveD iN 
SeNeSCeNCe
ASNCMTRNA2 (mtDNA-Transcribed  
Long-Non-Coding-RNA-2)
Villegas et  al. have first reported a mitochondrial transcript of 
2374 nucleotides whose expression correlates with the cellular 
replication (110). Following up this project, Burzio et  al. have 
reported the existence of two antisense mitochondrial tran-
scripts that were expressed in proliferating cells from healthy 
human tissues but decreased in tumor samples (111). Recently, 
Bianchessi et  al. showed that two miRNAs, hsa-miR-4485 and 
hsa-miR-1973, have perfect homology with ASncmtRNA-2. Both 
miRNAs are upregulated in endothelial cells at replicative senes-
cence. ASncmtRNA-2 overexpression results in an increased 
expression of hsa-miR-4485. It induces cell cycle arrest at G2/M 
phase. Moreover, the overexpression of the two miRNAs shows 
the similar phenotype, cell cycle delay in both the G1 and G2/M 
phases. They proposed that ASncmtRNA-2 is involved in replica-
tive senescence in endothelial cells by causing cell cycle arrest in 
the transition from G2/M to G1 (112).
MAiNTeNANCe OF SeNeSCeNCe
HOX Transcript Antisense RNA
The human lncRNA HOX transcript antisense RNA (HOTAIR) 
is transcribed from the HOXC locus of homeobox genes as an 
approximately 2.2-kb RNA (113). It binds to the enhancer of 
zeste homolog 2 (EZH2) in the polycomb repressive complex 
2 (PRC2) and to lysine-specific demethylase 1 (LSD1), which 
are chromatin remodeling factors (113, 114). Both complexes 
lead to gene silencing and are recruited in trans to hundreds of 
genomic sites by HOTAIR. Recently, Ozes et al demonstrated 
a novel function of HOTAIR in DDR, which is regulating the 
expression of genes to block proliferation. Their results showed 
that after induction of DNA damage, HOTAIR activates the 
cellular senescence through NF-κB pathway. Furthermore, 
they demonstrated the presence of a positive-feedback loop 
that induces HOTAIR. This activates DDR and sustains NF-κB 
expression (115). Recently, Yoon et  al. reported a function 
of lncRNA HOTAIR as a scaffold for ubiquitin-mediated 
proteolysis in posttranslational control (116). First, HOTAIR 
binds to E3 ubiquitin ligases through RNA-binding domains, 
Dzip3 and Mex3b, and to their ubiquitination targets: Ataxin-1 
and Snurportin-1, respectively. As a result, HOTAIR assists 
the ubiquitination of Ataxin-1 by Dzip3 and Snurportin-1 by 
Mex3b and speeds up their degradation. HOTAIR expression 
is increased in senescent cells, resulting in the degradation 
of Ataxin-1 and Snurportin-1 (116). Their results suggested 
a novel scaffold function for a lncRNA that can impact on 
senescence.
P21-Associated ncRNA DNA Damage 
Activated
With the help of super high-resolution tiling array analysis in 
CDKN1 region, Puvvula et al. identified P21-associated ncRNA 
DNA damage activated (PANDA) as a lncRNA, which is induced 
upon DNA damage.
P21-associated ncRNA DNA damage activated plays a dual 
role in proliferating cells versus senescent cells. In proliferating 
cells, scaffold-attachment-factor A/hnRNPU (SAFA) interacts 
with lncRNA PANDA to block senescence genes by recruiting 
PRC1 and PRC2 to senescence activating genes loci including 
CDKN1. Silencing SAFA and PANDA induces cell cycle arrest, 
and it also causes senescence in proliferating cells by allowing 
transcription of senescence activating genes.
In senescent cells, SAFA–PANDA–PRC interactions are 
blocked therefore, pro-senescence genes are transcribed. 
PANDA inhibits the expression of proliferative genes by 
sequestering the transcription factor NF-YA from occupying its 
target promoters in senescent cells. Depletion of PANDA in the 
senescent cells reactivates proliferative genes and allows cells to 
replicate (117).
CONCLUSiON AND PeRSPeCTiveS
As concluding remarks, with the recent advancement in technol-
ogy, our understanding on the function of lncRNAs has expanded 
vastly. Here, we have summarized an emerging role of lncRNAs as 
regulators of cellular senescence and age-related diseases. Albeit 
of these progresses, lncRNAs in senescence field is still in its 
infancy so as lncRNAs in general. Most of these studies remain 
at the cellular level, but the evidence that lncRNAs can regulate 
aging process in vivo has yet to be established.
Understanding lncRNAs function may help us fill some 
knowledge gap in genetic causes for human phenotypes. Many 
SNPs are not associated with coding genes but with non-coding 
region where lncRNAs may be transcribed (118). For example, a 
recent study on Asian centurions revealed a novel SNP rs2440012 
associated with longevity (119). Given the growing evidence of 
the functional role lncRNAs in physiological and pathological 
processes, we believe it is just a matter of time to illustrate role of 
lncRNAs in aging.
AUTHOR CONTRiBUTiONS
UD wrote the manuscript. SL reviewed and edited the manuscript.
ACKNOwLeDGMeNTS
This is a short text to acknowledge the contributions of specific 
colleagues, institutions, or agencies that aided the efforts of the 
authors.
FUNDiNG
This work was supported by Singapore NRF fellowship (NRF-
2011NRF-NRFF 001-025) to SL. This research is also supported 
by the Singapore National Research Foundation under its CBRG 
grant (NMRC/CBRG/0070/2014 and NMRC/CBRG/0101/2016) 
and administrated by the Singapore Ministry of Health’s National 
Medical Research Council. This work is also supported by 
A*STAR SINGA scholarship to UD.
8Degirmenci and Lei Role of lncRNAs in Cellular Aging
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 151
ReFeReNCeS
1. Armanios M. Telomeres and age-related disease: how telomere biology 
informs clinical paradigms. J Clin Invest (2013) 123(3):996–1002. 
doi:10.1172/JCI66370 
2. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally 
occurring p16Ink4a-positive cells shorten healthy lifespan. Nature (2016) 
530(7589):184–9. doi:10.1038/nature16932 
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The 
hallmarks of aging. Cell (2013) 153(6):1194–217. doi:10.1016/j.cell.2013. 
05.039 
4. van Deursen JM. The role of senescent cells in ageing. Nature (2014) 
509(7501):439–46. doi:10.1038/nature13193 
5. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathol-
ogy. Nat Rev Mol Cell Biol (2014) 15(7):482–96. doi:10.1038/nrm3823 
6. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. 
Genes Dev (2010) 24(22):2463–79. doi:10.1101/gad.1971610 
7. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker 
that identifies senescent human cells in culture and in aging skin in vivo. Proc 
Natl Acad Sci U S A (1995) 92:9363–7. 
8. Geng YQ, Guan JT, Xu XH, Fu YC. Senescence-associated beta-galactosidase 
activity expression in aging hippocampal neurons. Biochem Biophys Res 
Commun (2010) 396(4):866–9. doi:10.1016/j.bbrc.2010.05.011 
9. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et  al. 
Senescence-associated secretory phenotypes reveal cell-nonautonomous 
functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 
6(12):2853–68. doi:10.1371/journal.pbio.0060301 
10. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell 
Res (1965) 37:614–36. doi:10.1016/0014-4827(65)90211-9 
11. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. 
Exp Cell Res (1961) 25:585–621. doi:10.1016/0014-4827(61)90192-6 
12. Ungewitter E, Scrable H. Antagonistic pleiotropy and p53. Mech Ageing Dev 
(2009) 130(1–2):10–7. doi:10.1016/j.mad.2008.06.002 
13. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, et  al. 
Differential p53-independent outcomes of p19Arf loss in oncogenesis. 
Science (2009) 2(84):ra44. doi:10.1126/scisignal.2000053
14. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, 
et  al. Senescence and tumour clearance is triggered by p53 restoration in 
murine liver carcinomas. Nature (2007) 445(7128):656–60. doi:10.1038/
nature05529 
15. Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, et  al. 
Posttranslational modifications of p53 in replicative senescence overlapping 
but distinct from those induced by DNA damage. Mol Cell Biol (2000) 
20:2803–8. doi:10.1128/MCB.20.8.2803-2808.2000 
16. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular 
senescence. Int J Biochem Cell Biol (2005) 37(5):961–76. doi:10.1016/j.
biocel.2004.10.013 
17. Lim CS. Cellular senescence, cancer, and organismal aging: a paradigm 
shift. Biochem Biophys Res Commun (2006) 344(1):1–2. doi:10.1016/j.
bbrc.2006.03.161 
18. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, et al. Skp2 targeting 
suppresses tumorigenesis by Arf-p53-independent cellular senescence. 
Nature (2010) 464(7287):374–9. doi:10.1038/nature08815 
19. Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage 
response-independent regulator of the senescence-associated secretory 
phenotype. EMBO J (2011) 30(8):1536–48. doi:10.1038/emboj.2011.69 
20. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von 
Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated 
senescence. Nature (2003) 426(6963):194–8. doi:10.1038/nature02118 
21. Zhou B-BS, Elledge SJ. The DNA damage response: putting checkpoints in 
perspective. Nature (2000) 408(6811):433–9. doi:10.1038/35044005 
22. Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. 
Reversal of human cellular senescence: roles of p53 and p16 pathways. EMBO 
J (2003) 22:4212–22. doi:10.1093/emboj/cdg417
23. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de 
Sluis B, et  al. Clearance of p16Ink4a-positive senescent cells delays age-
ing-associated disorders. Nature (2011) 479(7372):232–6. doi:10.1038/ 
nature10600 
24. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, 
et al. p16INK4a induces an age-dependent decline in islet regenerative potential. 
Nature (2006) 443(7110):453–7. doi:10.1038/nature05092 
25. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, 
et  al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 
114(9):1299–307. doi:10.1172/JCI22475 
26. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, 
et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigen-
esis. Nature (2001) 413(6851):86–91. doi:10.1038/35092592
27. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement 
of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative 
senescence of normal human fibroblasts. PNAS (1996) 93(24):13742–7. 
doi:10.1073/pnas.93.24.13742 
28. Baker DJ, Perez-Terzic C, Jin F, Pitel KS, Niederländer NJ, Jeganathan K, et al. 
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by 
BubR1 insufficiency. Nat Cell Biol (2008) 10(7):825–36. doi:10.1038/ncb1744 
29. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular 
senescence is an important mechanism of tumor regression upon c-Myc 
inactivation. Proc Natl Acad Sci U S A (2007) 104(32):13028–33. doi:10.1073/
pnas.0701953104 
30. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras 
provokes premature cell senescence associated with accumulation of p53 and 
p16INK4a. Cell (1997) 88:593–602. 
31. Hampel B, Wagner M, Teis D, Zwerschke W, Huber LA, Jansen-Dürr 
P. Apoptosis resistance of senescent human fibroblasts is correlated 
with the absence of nuclear IGFBP-3. Aging Cell (2005) 4(6):325–30. 
doi:10.1111/j.1474-9726.2005.00180.x 
32. Ryu SJ, Oh YS, Park SC. Failure of stress-induced downregulation of Bcl-2 
contributes to apoptosis resistance in senescent human diploid fibroblasts. 
Cell Death Differ (2007) 14(5):1020–8. doi:10.1038/sj.cdd.4402091
33. Wenqi Chen JK, Kang J, Xia J, Li Y, Yang B, Chen B, et  al. p53-related 
apoptosis resistance and tumor suppression activity in UVB-induced pre-
mature senescent human skin fibroblasts. Int J Mol Med (2008) 21:645–53. 
doi:10.3892/ijmm.21.5.645
34. Pasillas MP, Shields S, Reilly R, Strnadel J, Behl C, Park R, et al. Proteomic 
analysis reveals a role for Bcl2-associated athanogene 3 and major vault 
protein in resistance to apoptosis in senescent cells by regulating ERK1/2 
activation. Mol Cell Proteomics (2015) 14(1):1–14. doi:10.1074/mcp.M114. 
037697 
35. Narita M, Nũnez S, Heard E, Narita M, Lin AW, Hearn SA, et al. Rb-mediated 
heterochromatin formation and silencing of E2F target genes during 
cellular senescence. Cell (2003) 113(6):703–16. doi:10.1016/S0092-8674(03) 
00401-X 
36. Macaluso M, Montanari M, Giordano A. Rb family proteins as modulators 
of gene expression and new aspects regarding the interaction with chro-
matin remodeling enzymes. Oncogene (2006) 25(38):5263–7. doi:10.1038/
sj.onc.1209680 
37. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in 
aging and age-related disease: from mechanisms to therapy. Nat Med (2015) 
21(12):1424–35. doi:10.1038/nm.4000 
38. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. 
A complex secretory program orchestrated by the inflammasome controls 
paracrine senescence. Nat Cell Biol (2013) 15(8):978–90. doi:10.1038/
ncb2784 
39. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB 
signaling in the induction of senescence-associated secretory phenotype 
(SASP). Cell Signal (2012) 24(4):835–45. doi:10.1016/j.cellsig.2011.12.006 
40. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Ann 
Rev Biochem (2012) 81:145–66. doi:10.1146/annurev-biochem-051410- 
092902 
41. Solé C, Nadal-Ribelles M, de Nadal E, Posas F. A novel role for lncRNAs in 
cell cycle control during stress adaptation. Curr Genet (2015) 61(3):299–308. 
doi:10.1007/s00294-014-0453-y 
42. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, 
et al. GENCODE: the reference human genome annotation for The ENCODE 
Project. Genome Res (2012) 22(9):1760–74. doi:10.1101/gr.135350.111 
43. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The 
GENCODE v7 catalog of human long noncoding RNAs: analysis of their 
9Degirmenci and Lei Role of lncRNAs in Cellular Aging
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 151
gene structure, evolution, and expression. Genome Res (2012) 22(9):1775–89. 
doi:10.1101/gr.132159.111 
44. Guttman M, Russell P, Ingolia NT, Weissman JS, Lander ES. Ribosome pro-
filing provides evidence that large non-coding RNAs do not encode proteins. 
Cell (2013) 154(1):240–51. doi:10.1016/j.cell.2013.06.009 
45. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: 
regulators of disease. J Pathol (2010) 220(2):126–39. doi:10.1002/path.2638 
46. Lu Q, Ren S, Lu M, Zhang Y, Zhu D, Zhang X, et al. Computational prediction 
of associations between long non-coding RNAs and proteins. BMC Genomics 
(2013) 14:651. doi:10.1186/1471-2164-14-651 
47. Li J, Xuan Z, Liu C. Long non-coding RNAs and complex human diseases. Int 
J Mol Sci (2013) 14(9):18790–808. doi:10.3390/ijms140918790 
48. Andrews SJ, Rothnagel JA. Emerging evidence for functional peptides 
encoded by short open reading frames. Nat Rev Genet (2014) 15(3):193–204. 
doi:10.1038/nrg3520 
49. Gascoigne DK, Cheetham SW, Cattenoz PB, Clark MB, Amaral PP, Taft 
RJ, et  al. Pinstripe: a suite of programs for integrating transcriptomic and 
proteomic datasets identifies novel proteins and improves differentiation of 
protein-coding and non-coding genes. Bioinformatics (2012) 28(23):3042–50. 
doi:10.1093/bioinformatics/bts582 
50. Ingolia NT, Lareau LF, Weissman JS. Ribosome profiling of mouse embryonic 
stem cells reveals the complexity of mammalian proteomes. Cell (2011) 
147(4):789–802. doi:10.1016/j.cell.2011.10.002 
51. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell 
(2013) 154(1):26–46. doi:10.1016/j.cell.2013.06.020 
52. Elling R, Chan J, Fitzgerald KA. Emerging role of long noncoding 
RNAs as regulators of innate immune cell development and inflamma-
tory  gene  expression. Eur J Immunol (2016) 46(3):504–12. doi:10.1002/eji. 
201444558 
53. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. 
Landscape of transcription in human cells. Nature (2012) 489(7414):101–8. 
doi:10.1038/nature11233 
54. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. 
Many human large intergenic noncoding RNAs associate with chroma-
tin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S 
A (2009) 106(28):11667–72. doi:10.1073/pnas.0904715106 
55. Mondal T, Rasmussen M, Pandey GK, Isaksson A, Kanduri C. Characterization 
of the RNA content of chromatin. Genome Res (2010) 20(7):899–907. 
doi:10.1101/gr.103473.109 
56. McHugh CA, Chen CK, Chow A, Surka CF, Tran C, McDonel P, et al. The 
Xist lncRNA directly interacts with SHARP to silence transcription through 
HDAC3. Nature (2015) 521(7551):232–6. doi:10.1038/nature14443 
57. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional sur-
prises from the RNA world. Genes Dev (2009) 23(13):1494–504. doi:10.1101/
gad.1800909 
58. Chaumeil J, Le Baccon P, Wutz A, Heard E. A novel role for Xist RNA in 
the formation of a repressive nuclear compartment into which genes are 
recruited when silenced. Genes Dev (2006) 20(16):2223–37. doi:10.1101/ 
gad.380906 
59. Hu G, Tang Q, Sharma S, Yu F, Escobar TM, Muljo SA, et al. Expression and 
regulation of lincRNAs during T cell development and differentiation. Nat 
Immunol (2013) 14(11):1190–8. doi:10.1038/ni.2712 
60. Casero D, Sandoval S, Seet CS, Scholes J, Zhu Y, Ha VL, et  al. LncRNA 
profiling of human lymphoid progenitors reveals transcriptional divergence 
of B and T lineages. Nat Immunol (2015) 16(12):1282–91. doi:10.1038/ 
ni.3299 
61. Jiang K, Sun X, Chen Y, Shen Y, Jarvis JN. RNA sequencing from human 
neutrophils reveals distinct transcriptional differences associated with 
chronic inflammatory states. BMC Med Genomics (2015) 8:55. doi:10.1186/
s12920-015-0128-7 
62. Werner MS, Ruthenburg AJ. Nuclear fractionation reveals thousands of chro-
matin-tethered noncoding RNAs adjacent to active genes. Cell Rep (2015) 
12(7):1089–98. doi:10.1016/j.celrep.2015.07.033 
63. Ounzain S, Pedrazzini T. Super-enhancer lncs to cardiovascular development 
and disease. Biochim Biophys Acta (2016) 1863(7 Pt B):1953–60. doi:10.1016/j.
bbamcr.2015.11.026 
64. Lai F, Gardini A, Zhang A, Shiekhattar R. Integrator mediates the biogen-
esis of enhancer RNAs. Nature (2015) 525(7569):399–403. doi:10.1038/
nature14906 
65. Pott S, Lieb JD. What are super-enhancers? Nat Genet (2015) 47(1):8–12. 
doi:10.1038/ng.3167 
66. Quinn JJ, Chang HY. RNA switch at enhancers. Nat Genet (2014) 46(9):929–
31. doi:10.1038/ng.3074 
67. Bonasio R, Shiekhattar R. Regulation of transcription by long 
noncoding RNAs. Annu Rev Genet (2014) 48:433–55. doi:10.1146/
annurev-genet-120213-092323 
68. Orom UA, Shiekhattar R. Long noncoding RNAs usher in a new era 
in the biology of enhancers. Cell (2013) 154(6):1190–3. doi:10.1016/j.
cell.2013.08.028 
69. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et  al. 
Transcriptional super-enhancers connected to cell identity and disease. Cell 
(2013) 155(4):53. doi:10.1016/j.cell.2013.09.053 
70. Li H, Gade P, Nallar SC, Raha A, Roy SK, Karra S, et al. The Med1 subunit 
of transcriptional mediator plays a central role in regulating CCAAT/
enhancer-binding protein-beta-driven transcription in response to 
interferon-gamma. J Biol Chem (2008) 283(19):13077–86. doi:10.1074/jbc.
M800604200 
71. Blackwood EM, Kadonaga JT. Going the distance: a current view of 
enhancer action. Science (1998) 281(5373):60–3. doi:10.1126/science.281. 
5373.60 
72. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation 
and development. Nat Rev Genet (2014) 15(1):7–21. doi:10.1038/nrg3606 
73. Schaukowitch K, Kim TK. Emerging epigenetic mechanisms of long 
non-coding RNAs. Neuroscience (2014) 264:25–38. doi:10.1016/j.
neuroscience.2013.12.009 
74. Clark BS, Blackshaw S. Long non-coding RNA-dependent transcriptional 
regulation in neuronal development and disease. Front Genet (2014) 5:164. 
doi:10.3389/fgene.2014.00164 
75. Lee JT. Epigenetic regulation by long noncoding RNAs. Science (2012) 
338:1435–9. doi:10.1126/science.1231776 
76. Pefanis E, Wang J, Rothschild G, Lim J, Kazadi D, Sun J, et  al. RNA exo-
some-regulated long non-coding RNA transcription controls super-enhancer 
activity. Cell (2015) 161(4):774–89. doi:10.1016/j.cell.2015.04.034 
77. Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear 
structure and function. Curr Opin Cell Biol (2014) 26:10–8. doi:10.1016/j.
ceb.2013.08.005 
78. Niederer RO, Papadopoulos N, Zappulla DC. Identification of novel noncod-
ing transcripts in telomerase-negative yeast using RNA-seq. Sci Rep (2016) 
6:19376. doi:10.1038/srep19376 
79. Kozlowski M, Ladurner AG. ATM, MacroH2A.1, and SASP: the checks and 
balances of cellular senescence. Mol Cell (2015) 59(5):713–5. doi:10.1016/j.
molcel.2015.08.010 
80. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, et  al. A functional 
genomic approach identifies FAL1 as an oncogenic long noncoding RNA 
that associates with BMI1 and represses p21 expression in cancer. Cancer 
Cell (2014) 26(3):344–57. doi:10.1016/j.ccr.2014.07.009 
81. Zhong X, Hu X, Zhang L. Oncogenic long noncoding RNA FAL1 in human 
cancer. Mol Cell Oncol (2015) 2(2):e977154. doi:10.4161/23723556.2014.97
7154 
82. Zhang ZX, Liu ZQ, Jiang B, Lu XY, Ning XF, Yuan CT, et al. BRAF activated 
non-coding RNA (BANCR) promoting gastric cancer cells proliferation via 
regulation of NF-κB1. Biochem Biophys Res Commun (2015) 465(2):225–31. 
doi:10.1016/j.bbrc.2015.07.158 
83. Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, et al. Downregulation 
of BRAF activated non-coding RNA is associated with poor prognosis for 
non-small cell lung cancer and promotes metastasis by affecting epithelial- 
mesenchymal transition. Mol Cancer (2014) 13:68–68. doi:10.1186/ 
1476-4598-13-68 
84. Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. 
BRAF(V600E) remodels the melanocyte transcriptome and induces BANCR 
to regulate melanoma cell migration. Genome Res (2012) 22(6):1006–14. 
doi:10.1101/gr.140061.112 
85. Shi Y, Liu Y, Wang J, Jie D, Yun T, Li W, et al. Downregulated long noncoding 
RNA BANCR promotes the proliferation of colorectal cancer cells via down-
regualtion of p21 expression. PLoS One (2015) 10(4):e0122679. doi:10.1371/
journal.pone.0122679 
86. Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, 
et  al. LincRNA-p21 activates p21 In cis to promote polycomb target gene 
10
Degirmenci and Lei Role of lncRNAs in Cellular Aging
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 151
expression and to enforce the G1/S checkpoint. Mol Cell (2014) 54(5):777–90. 
doi:10.1016/j.molcel.2014.04.025 
87. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, 
et  al. LincRNA-p21 suppresses target mRNA translation. Mol Cell (2012) 
47(4):648–55. doi:10.1016/j.molcel.2012.06.027 
88. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. 
Nat Rev Cancer (2005) 5(5):367–75. doi:10.1038/nrc1610 
89. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, 
Chess A. A screen for nuclear transcripts identifies two linked noncoding 
RNAs associated with SC35 splicing domains. BMC Genomics (2007) 8(1):39. 
doi:10.1186/1471-2164-8-39 
90. Spector DL, Lamond AI. Nuclear speckles. Cold Spring Harb Perspect Biol 
(2011) 3(2):a000646. doi:10.1101/cshperspect.a000646 
91. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-re-
tained noncoding RNA MALAT1 regulates alternative splicing by mod-
ulating SR splicing factor phosphorylation. Mol Cell (2010) 39(6):925–38. 
doi:10.1016/j.molcel.2010.08.011 
92. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et  al. Long 
noncoding RNA MALAT1 controls cell cycle progression by regulating the 
expression of oncogenic transcription factor B-MYB. PLoS Genet (2013) 
9(3):e1003368. doi:10.1371/journal.pgen.1003368 
93. Sakamoto K, Fordis CM, Corsico CD, Howard TH, Howard BH. Modulation 
of HeLa cell growth by transfected 7SL RNA and Alu gene sequences. J Biol 
Chem (1991) 266(5):3031–8. 
94. Abdelmohsen K, Panda AC, Kang MJ, Guo R, Kim J, Grammatikakis I, et al. 
7SL RNA represses p53 translation by competing with HuR. Nucleic Acids Res 
(2014) 42(15):10099–111. doi:10.1093/nar/gku686 
95. Lazorthes S, Vallot C, Briois S, Aguirrebengoa M, Thuret JY, St Laurent 
G, et  al. A vlincRNA participates in senescence maintenance by relieving 
H2AZ-mediated repression at the INK4 locus. Nat Commun (2015) 6:5971. 
doi:10.1038/ncomms6971 
96. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long 
non-coding RNA ANRIL is required for the PRC2 recruitment to and silenc-
ing of p15(INK4B) tumor suppressor gene. Oncogene (2011) 30(16):1956–62. 
doi:10.1038/onc.2010.568 
97. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et  al. 
Molecular interplay of the noncoding RNA ANRIL and methylated histone 
H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. 
Mol Cell (2010) 38(5):662–74. doi:10.1016/j.molcel.2010.03.021 
98. Shi Y, Lu J, Zhou J, Tan X, He Y, Ding J, et al. Long non-coding RNA Loc554202 
regulates proliferation and migration in breast cancer cells. Biochem Biophys 
Res Commun (2014) 446(2):448–53. doi:10.1016/j.bbrc.2014.02.144 
99. Montes M, Nielsen MM, Maglieri G, Jacobsen A, Højfeldt J, Agrawal-Singh S, 
et al. The lncRNA MIR31HG regulates p16(INK4A) expression to modulate 
senescence. Nat Commun (2015) 6:6967. doi:10.1038/ncomms7967 
100. Kumar PP, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, 
et  al. Coordinated control of senescence by lncRNA and a novel 
T-box3  co- repressor complex. Elife (2014) 3:e02805. doi:10.7554/eLife. 
02805 
101. Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA 
with a crucial role in cancer. J Cancer Res Clin Oncol (2016) 142(7):1407–19. 
doi:10.1007/s00432-015-2042-y 
102. Abdelmohsen K, Panda A, Kang MJ, Xu J, Selimyan R, Yoon JH, et  al. 
Senescence-associated lncRNAs: senescence-associated long noncoding 
RNAs. Aging Cell (2013) 12(5):890–900. doi:10.1111/acel.12115 
103. Wu CL, Wang Y, Jin B, Chen H, Xie BS, Mao ZB. Senescence-associated Long 
Non-coding RNA (SALNR) Delays Oncogene-induced Senescence through 
NF90 Regulation. J Biol Chem (2015) 290(50):30175–92. doi:10.1074/jbc.
M115.661785 
104. Arnoult N, Van Beneden A, Decottignies A. Telomere length regulates 
TERRA levels through increased trimethylation of telomeric H3K9 
and HP1α. Nat Struct Mol Biol (2012) 19(9):948–56. doi:10.1038/ 
nsmb.2364 
105. Deng Z, Wang Z, Xiang C, Molczan A, Baubet V, Conejo-Garcia J, et  al. 
Formation of telomeric repeat-containing RNA (TERRA) foci in highly 
proliferating mouse cerebellar neuronal progenitors and medulloblastoma. 
J Cell Sci (2012) 125(18):4383–94. doi:10.1242/jcs.108118 
106. Balk B, Maicher A, Dees M, Klermund J, Luke-Glaser S, Bender K, et  al. 
Telomeric RNA-DNA hybrids affect telomere-length dynamics and senes-
cence. Nat Struct Mol Biol (2013) 20(10):1199–205. doi:10.1038/nsmb.2662 
107. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric 
repeat–containing RNA and RNA surveillance factors at mammalian 
chromosome ends. Science (2007) 318(5851):798–801. doi:10.1126/science. 
1147182 
108. Porro A, Feuerhahn S, Lingner J. TERRA-reinforced association of LSD1 
with MRE11 promotes processing of uncapped telomeres. Cell Rep (2014) 
6(4):765–76. doi:10.1016/j.celrep.2014.01.022 
109. Lustig AJ. Telomerase RNA: a flexible RNA scaffold for telomerase biosynthe-
sis. Curr Biol (2004) 14(14):R565–7. doi:10.1016/j.cub.2004.07.013 
110. Villegas J, Burzio V, Villota C, Landerer E, Martinez R, Santander M, et al. 
Expression of a novel non-coding mitochondrial RNA in human proliferat-
ing cells. Nucleic Acids Res (2007) 35(21):7336–47. doi:10.1093/nar/gkm863 
111. Burzio VA, Villota C, Villegas J, Landerer E, Boccardo E, Villa LL, et  al. 
Expression of a family of noncoding mitochondrial RNAs distinguishes 
normal from cancer cells. Proc Natl Acad Sci U S A (2009) 106(23):9430–4. 
doi:10.1073/pnas.0903086106 
112. Bianchessi V, Badi I, Bertolotti M, Nigro P, D’Alessandra Y, Capogrossi MC, 
et al. The mitochondrial lncRNA ASncmtRNA-2 is induced in aging and rep-
licative senescence in Endothelial Cells. J Mol Cell Cardiol (2015) 81:62–70. 
doi:10.1016/j.yjmcc.2015.01.012 
113. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et  al. 
Functional demarcation of active and silent chromatin domains in human 
HOX loci by noncoding RNAs. Cell (2007) 129(7):1311–23. doi:10.1016/j.
cell.2007.05.022 
114. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long 
noncoding RNA as modular scaffold of histone modification complexes. 
Science (2010) 329(5992):689–93. doi:10.1126/science.1192002 
115. Ozes AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, et  al. NF-kappaB-
HOTAIR axis links DNA damage response, chemoresistance and cellular 
senescence in ovarian cancer. Oncogene (2016) 35(41):5350–61. doi:10.1038/
onc.2016.75 
116. Yoon J-H, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-
Yamanaka K, et  al. Scaffold function of long non-coding RNA HOTAIR 
in protein ubiquitination. Nat Commun (2013) 4:2939. doi:10.1038/
ncomms3939 
117. Puvvula PK, Desetty RD, Pineau P, Marchio A, Moon A, Dejean A, et  al. 
Long noncoding RNA PANDA and scaffold-attachment-factor SAFA 
control senescence entry and exit. Nat Commun (2014) 5:5323. doi:10.1038/
ncomms6323 
118. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et  al. The 
landscape of long noncoding RNAs in the human transcriptome. Nat Genet 
(2015) 47(3):199–208. doi:10.1038/ng.3192 
119. Zeng Y, Nie C, Min J, Liu X, Li M, Chen H, et al. Novel loci and pathways 
significantly associated with longevity. Sci Rep (2016) 6:21243. doi:10.1038/
srep21243 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Degirmenci and Lei. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
